PPAR
Peroxisome Proliferator-Activated Receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes involved in metabolism, particularly fatty acid storage and glucose metabolism. PPAR inhibitors are important tools for studying metabolic disorders such as diabetes, obesity, and cardiovascular diseases. These inhibitors can modulate lipid metabolism, insulin sensitivity, and inflammation, making them valuable in therapeutic research. At CymitQuimica, we offer a range of PPAR inhibitors to support your research in metabolic diseases, endocrinology, and drug development.
Found 170 products of "PPAR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Amezalpat
CAS:Amezalpat is a PPARα antagonist with an IC50 of 58 nM [nanomolar]. Amezalpat also exhibits antitumor activity.Formula:C34H41N3O4Color and Shape:SolidMolecular weight:555.707PPARγ-IN-5
CAS:PPARγ-IN-5 (Compound A3) is an inhibitor of PPARγ. In liver cells, it reduces lipid accumulation and shows no significant cytotoxicity in HepG2 cells at a concentration of 400 µM. PPARγ-IN-5 is applicable for research on non-alcoholic fatty liver disease.Formula:C22H23ClO7Color and Shape:SolidMolecular weight:434.867PPARα/δ agonist 3
CAS:PPARα/δ agonist 3 (Compound 8) is an orally active PPAR agonist capable of activating PPARα, PPARδ, and PPARγ, with EC50 values of 5.6 nM, 3.4 nM, and 1278 nM, respectively. It exhibits anti-cholestatic activity in mouse models of cholestatic liver disease induced by ANIT or CDCA.Formula:C23H25F3N2O4Color and Shape:SolidMolecular weight:450.451PPARδ agonist 11
CAS:Compound 11, a selective PPARδ agonist, demonstrates an EC50 of 20 nM, indicating its high affinity for PPARδ receptors. This compound efficiently reduces levels of nitric oxide (NO), as well as the pro-inflammatory cytokines TNFα and IL-6 in LPS-stimulated RAW264.7 cells via the NF-κB pathway, showcasing its anti-inflammatory properties. Additionally, Compound 11 exhibits remarkable stability in human liver microsomes and plasma. It significantly ameliorates foot edema induced by Carrageenan, displaying favorable pharmacokinetic properties with a bioavailability of approximately 100%.Formula:C19H15F3N2O3S2Color and Shape:SolidMolecular weight:440.46Fonadelpar
CAS:Fonadelpar is an agonist of PPARδ. It also is used in the research of neuroparalytic keratopathy.Formula:C25H23F3N2O4SPurity:98%Color and Shape:SolidMolecular weight:504.52PPARγ agonist 10
CAS:PPARγ agonist 10 (compound 33g) serves as a PPARγ agonist, enhancing insulin secretion, glucose uptake, and insulin sensitivity in βTC6 cells [1].Formula:C17H14N4O3S2Color and Shape:SolidMolecular weight:386.45Aleglitazar
CAS:Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively.Formula:C24H23NO5SPurity:99.03%Color and Shape:SolidMolecular weight:437.51Ref: TM-T14176
1mg233.00€5mg532.00€10mg718.00€25mg1,099.00€50mg1,485.00€100mg1,998.00€1mL*10mM (DMSO)538.00€PPARγ-IN-2
CAS:"PPARγ-IN-2 (Compound 5a), a PPARγ inhibitor, exhibits an EC50 of 0.106 μM in inhibiting TG accumulation in 3T3-L1 preadipocytes.
Formula:C19H21N5OPurity:98%Color and Shape:SolidMolecular weight:335.4Mavodelpar free base
CAS:Mavodelpar free acid (REN001 free acid) is an selective agonist of PPARδ.
Formula:C31H30FNO5Purity:98%Color and Shape:SolidMolecular weight:515.57Anti-NASH agent 1
CAS:Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α/δ agonist aimed at treating nonalcoholic steatohepatitis (NASH).
Formula:C26H33NO4Purity:98%Color and Shape:SolidMolecular weight:423.54
